The market is driven by increase in investments in vaccines segment, public immunization programs funded by governments, and improved public access to information about vaccines
1h Free Analyst Time
The human vaccine market is forecasted to grow by USD 29.1 bn during 2023-2028, accelerating at a CAGR of 9.49% during the forecast period. The report on the human vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in pediatric population, need for novel vaccines for chronic infections, and public immunization programs funded by governments.
The human vaccine market is segmented as below:
By Route Of Administration
- Intramuscular
- Subcutaneous
- Oral
By End-user
- Pediatrics
- Adults
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the human vaccine market covers the following areas:
- Human vaccine market sizing
- Human vaccine market forecast
- Human vaccine market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global human vaccine market: Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Group Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Serum Institute of India Pvt. Ltd., and Sanofi SA.Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is R and D of novel vaccines.'
According to the report, one of the major drivers for this market is the increase in pediatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bavarian Nordic AS
- Bharat Biotech Ltd.
- BioNTech SE
- CanSino Biologics Inc.
- CSL Ltd.
- Daiichi Sankyo Co. Ltd.
- Emergent BioSolutions Inc.
- GlaxoSmithKline Plc
- Gradalis Inc.
- Inovio Pharmaceuticals Inc.
- Johnson and Johnson
- Merck and Co. Inc.
- Mitsubishi Chemical Group Corp.
- Moderna Inc.
- Novavax Inc.
- Pfizer Inc.
- Serum Institute of India Pvt. Ltd.
- Sanofi SA
